The application of TPD technologies to CNS targets is a huge area of untapped potential to tackle the unmet need against undruggable neurological proteins.
With innovative biotechs paving the way and CNS and TPD large biopharma expanding their pipelines, there is an equally large untapped opportunity to showcase your solutions and help industry overcome their translational challenges and accelerate CNS degraders into the clinic.
At the Targeted Protein Degradation for CNS Summit, there are a limited number of partnership opportunities available, including speaking positions on the agenda, exhibition booths, and private networking opportunities.
If you provide services or technologies that would benefit our niche industry audience, now is the time to secure new business and form connections with top biopharma companies seeking solutions to progress their products CNS degraders into the clinic.
"The strategy of targeted protein degradation is shifting drug discovery from functional inhibitors to proteolytic degraders of targeted proteins. This meeting will provide current advances of the fields in CNS diseases."
Bicentennial Chair & Professor, Indiana University School of Medicine
Chairman & Co-Founder, Degrome Therapeutics
Experts Need Your Help With:
Discovery CROs to screen and identify new small molecule hits for protein degraders against CNS targets
In vitro and in vivo BBB model providers to predict and demonstrate delivery to the CNS
Preclinical CROs specializing in CNS and TPD for safety and efficacy testing
CNS biomarker and assay providers to test degrader target engagement and mechanism of action
Target developers providing novel insights in tackling CNS disease proteins
Showcase your solutions to an exclusive group of TPD and CNS experts from leading biopharma companies seeking high-level support and long-term commercial partners
Get ahead of your competitors in this emerging field by demonstrating your experience in discovery and preclinical degrader development
Elevate your company’s standing in the field, demonstrating your ability to keep up with high-pressured timelines, solving this field's unique challenges